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19). The optimal selection of interventions targeting the virus is unknown. Therefore, evidence from
randomized controlled trials (RCTs) to support specific treatment against COVID-19 is urgently needed.
The use of Chinese herbal medicines (CHMs) might have a role in the treatment and symptomatic man-
agement of patients with COVID-19. It was aimed at providing an overview of the available evidence
and ongoing trials concerning the effects of CHMs for the treatment of COVID-19. Methods: This is a
narrative review of relevant studies. Searches were conducted to identify documents published till April
22, 2020. Electronic databases, evidence-based collections, websites of relevant organizations, and trial
registries were consulted. Results: A total of 25 guidelines on the treatment of patients with COVID-19
were identified. Four guidelines provided recommendations on the use of CHMs; these guidelines were de-
veloped in China and South Korea and were based on the consensus of experts exclusively. The remaining
21 guidelines provided no guidance on CHMs. No finished RCTs of CHMs for the treatment of patients
with COVID-19 was found. According to the evidence evaluated in this review, a Cochrane review of
CHMs for severe acute respiratory syndrome and five uncontrolled observational studies of the effects
of CHMs in patients with COVID-19, the effects of CHMs for COVID-19 are unknown. A total of 52
ongoing clinical trials of CHM interventions for the treatment of COVID-19 were found. These trials will
be carried out mostly in China (n = 51). Forty (77%) of the ongoing trials will be randomized, whereas
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size <400 participants. Conclusions: To the authors’ knowledge, only the Chinese and the South Korean
guidelines recommend CHMs as a treatment option for patients with COVID-19. These guidelines base
their recommendations on the consensus of experts. Clinical guidelines or health authorities from other
countries do not provide advice on CHMs. Due to the absence of RCT, there is currently no reliable
evidence on the effects of any specific CHM intervention for the treatment of patients with COVID-19.
A high number of clinical trials of different herbal products are being currently conducted in China.
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Abstract
Background: There is currently no effective treatment against coronavirus disease 2019 (COVID-19). The
optimal selection of interventions targeting the virus is unknown. Therefore, evidence from randomized con-
trolled trials (RCTs) to support specific treatment against COVID-19 is urgently needed. The use of Chinese
herbal medicines (CHMs) might have a role in the treatment and symptomatic management of patients with
COVID-19. It was aimed at providing an overview of the available evidence and ongoing trials concerning the
effects of CHMs for the treatment of COVID-19.
Methods: This is a narrative review of relevant studies. Searches were conducted to identify documents
published till April 22, 2020. Electronic databases, evidence-based collections, websites of relevant organi-
zations, and trial registries were consulted.
Results: A total of 25 guidelines on the treatment of patients with COVID-19 were identified. Four guidelines
provided recommendations on the use of CHMs; these guidelines were developed in China and South Korea and
were based on the consensus of experts exclusively. The remaining 21 guidelines provided no guidance on
CHMs. No finished RCTs of CHMs for the treatment of patients with COVID-19 was found. According to the
evidence evaluated in this review, a Cochrane review of CHMs for severe acute respiratory syndrome and five
uncontrolled observational studies of the effects of CHMs in patients with COVID-19, the effects of CHMs for
COVID-19 are unknown. A total of 52 ongoing clinical trials of CHM interventions for the treatment of
COVID-19 were found. These trials will be carried out mostly in China (n= 51). Forty (77%) of the ongoing
trials will be randomized, whereas 12 (23%) have an unclear sequence generation procedure. Forty-seven trials
(90%) will have a sample size <400 participants.
Conclusions: To the authors’ knowledge, only the Chinese and the South Korean guidelines recommend
CHMs as a treatment option for patients with COVID-19. These guidelines base their recommendations on the
consensus of experts. Clinical guidelines or health authorities from other countries do not provide advice on
CHMs. Due to the absence of RCT, there is currently no reliable evidence on the effects of any specific CHM
intervention for the treatment of patients with COVID-19. A high number of clinical trials of different herbal
products are being currently conducted in China.
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6Center for Integrative Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE




























































Coronavirus disease 2019 (COVID-19) is an acute re-spiratory disease caused by severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2). COVID-19 has
rapidly spread globally since an outbreak first reported in
Wuhan in December 2019. As declared by the World Health
Organization (WHO) on March 11, COVID-19 is a ‘‘public
health emergency of international concern,’’ and the pan-
demic is overloading health care facilities worldwide.
There is currently no effective treatment against COVID-
19. The optimal selection of antiviral agents and interven-
tions targeting the virus is unknown. Therefore, high-quality
evidence from randomized controlled trials (RCTs) to sup-
port decisions concerning the treatment of COVID-19 is
urgently needed.
Traditional Chinese Medicine (TCM) is an essential part of
the health care system in China.1,2 The WHO recognizes this
situation and supports theMember States of theWestern Pacific
Region to integrate traditionalmedicine into their national health
systems.3 In this line, the WHO International Classification of
Diseases (ICD 11) has introduced a new chapter on traditional
medicine.4 TCM is also used in Western countries and is rec-
ognized as a complementary or alternative medicine.5–7
Chinese herbal medicines (CHMs) are an essential part of
TCM.7 CHMs include single herbs, Chinese proprietary medi-
cines, and mixtures of different herbs,8 which might be used
alone or in combination with Western medicines. CHMs might
have a role in the treatment and symptomaticmanagement of pa-
tients with COVID-19.9,10 Herbal plants are routinely used for
treating viral respiratory infections in China and might have
compoundswith capacity against 2019-nCoV.11CHMs are con-
sidered to have a generalized antiviral effect based on the direct
inhibition of viruses, and the control of the associated inflam-
matory response. Previous in vitro studies of Chinese medicinal
herbs have suggested their antiviral activity. For instance,Weng
et al. demonstrated the activity of Sambucus Formosana Nakai
ethanol extract against human coronavirus NL63.12
The state administration of TCM of the People’s Republic
of China, in collaboration with the WHO, initiated clinical
research projects on integrated TCM and conventional med-
icine for the management of SARS.13 A total of 21 projects
covering prevention and treatment were already started, but
firm conclusions on intervention efficacy could not be drawn
yet. Experts recommended WHO continue to support the
research of TCM in treating SARS and other diseases.13
The Institute for Complementary and Integrative Medi-
cine14 (Zurich University Hospital) has prepared this report
to summarize the evidence concerning CHMs for the
treatment of COVID-19. This review has three specific
objectives. First, to describe the recommendations on the
use of CHMs for the treatment of COVID-19 in clinical
guidelines and documents of relevant organizations. Second,
to summarize the evidence on CHMs in patients with
COVID-19. Third, to provide an overview of the ongoing
RCTs of CHMs in patients with COVID-19.
Materials and Methods
This study is a scoping review and did not require written
consent or institutional ethical review because it is based on
published work exclusively.
Inclusion and exclusion criteria
Type of study designs. The focus of this review was to
identify rigorous secondary research and RCTs on this re-
view topic. Thus, we looked for evidence-based clinical
guidelines, health technology assessments, systematic re-
views, and RCTs. If there was no secondary research or
RCTs available, nonrandomized trials were looked for, that
is, quasi-randomized controlled trials (quasi-RCTs) and
nonrandomized clinical trials. Only if previous designs were
not found, observational studies, narrative reviews, and
opinion of experts were included. Since it was expected that
the evidence base would be scarce or absent, systematic
reviews on the effects of CHMs in patients with SARS were
also included.
Types of participants. Patients with COVID-19 (the di-
agnosis as provided by the study authors was accepted).
A specific set of diagnostic criteria was not required as these
have changed since the beginning of the outbreak.
Types of interventions. Studies evaluating the use of
CHMs (combined or not with conventional medicines) for
the treatment of patients with COVID-19 were included. To
classify an intervention as CHMs, the operational definition
provided by the Cochrane review on Chinese herbs com-
bined with Western medicine for SARS was followed.8,15
Consequently, Chinese herbs were defined as ‘‘either raw or
refined products derived from plants or parts of plants (e.g.,
leaves, stems, buds, flowers, roots, or tubers) used for
treating diseases.’’8,15 Therefore, this review also covered
herbal products used in other countries besides China under
the Traditional Eastern Asian Medicine, such as South
Korea and Japan. This includes decoction of raw herbs
prepared in medical facilities, or concentrated herbal ex-
tracts provided according to good manufacture practices by
pharmaceutical companies.
This review excluded other interventions defined in
Western countries as complementary, alternative, or inte-
grative therapies, such as the use of vitamins or other food
supplements, mind–body exercises (e.g., t’ai chi, yoga),
psychotherapy, or acupuncture.
We included studies with any comparator and coin-
terventions. To include a study, the cointerventions should
be similar in both study groups to allow determining the
effects of CHMs.
Types of outcome measures. It was planned to assess
the following outcomes measured at the end of treatment or
the end of follow-up: all-cause mortality; COVID-19–
related mortality; days to loss of fever; symptom scores
(symptoms included fever, fatigue, cough, poor appetite,
perspiration, constipation, and diarrhea); duration of symp-
toms; duration of absorption of pulmonary infiltration; ab-
sorption of pulmonary infiltration (assessed with chest
X-ray); average daily dose of corticosteroid; dosage of
corticosteroid at the end of treatment; duration of cortico-
steroid treatment; quality of life; number of days in the
hospital; and adverse effects. These outcomes were similar
to those measured in a Cochrane review of Chinese herbs
combined with Western medicine for SARS.8


























































Search methods for identification of studies
Literature searches were conducted looking for docu-
ments published till April 22, 2020, with no language of
publication restriction. The following sources were con-
sulted: (a) electronic databases (Tripdatabase; MEDBOX
Rapid Response Toolbox; Epistemonikos; The Cochrane
Database of Systematic Reviews [CDSR], and The Co-
chrane Central Register of Controlled Trials [CENTRAL]);
(b) evidence-based collections; and (c) websites of relevant
organizations. Experts in China were also contacted asking
for related studies or guidelines. To identify ongoing RCTs
evaluating interventions for the treatment of COVID-19, the
Cochrane COVID-19 Study Register was consulted.16 Ap-
pendix A1 details the search strategies used. The results of
the searches were managed with the software Endnote X7.17
Analysis methods
A narrative description of the evidence found was provided
and any meta-analysis was not foreseen to be performed.
Results
AppendixA2 lists all the documents consulted for this report.
Description of the studies
The electronic searches until April 23, 2020, identified a
total of 641 records after removal of duplicates. The review
finally included 25 guidelines, 1 systematic review, no RCT,
and 52 ongoing trials (40 RCTs and 12 trials with unclear
randomization). Figure 1 presents a flow diagram describing
the results of the searches and the selection process.
Objective 1: To describe the recommendations on the use
of CHMs for the treatment of COVID-19 in clinical guidelines
and documents of relevant organizations
We identified a total of 25 guidelines providing recom-
mendations on the treatment of patients with COVID-19
(Appendix A2). The guidelines were published in the fol-
lowing countries: United States (n= 5),18–22United Kingdom
(n= 4),23–26 Canada (n= 3),27–29 China (n = 3, reported in 4
publications),30–33 Australia (n = 2),34,35 Germany (n = 1),36
South Korea (n = 2),37,38 and Malaysia (n= 1).39 International
organizations developed the remaining guidelines (n = 4), that
is, theWHO,40,41 the European Centre for Disease Prevention
andControl (ECDC),42 and the Surviving Sepsis Campaign.43
Sixty percent of the assessed guidelines were developed in
Western countries (n = 15), whereas 24% (n = 6) in Asia.
The three Chinese guidelines30–32 and the Korean Tradi-
tional Medicine guidelines38 were the only ones providing
recommendations on CHMs for the treatment of COVID-19.
The Surviving Sepsis Campaign guidelines43 did not provide
any recommendation on CHMs, but they stated that several
TCMs are undergoing testing. The remaining 20 guidelines
(80%)18–29,33–37,39–42 provided no information on CHMs. Two
additional guidelines44,45 were not included in our analysis as,
although covering Traditional Chinese Medicine, the focus
was on acupuncture.
FIG. 1. Flow chart. CDSR, Cochrane Database of Systematic Reviews; CENTRAL, Cochrane Central Register of
Controlled Trials; CHM, Chinese herbal medicine; RCT, randomized controlled trial; SRs, systematic reviews; TCM,
Traditional Chinese Medicine.


























































The three Chinese guidelines30–32 and the Korean Tradi-
tional Medicine guidelines38 recommend CHMs as a treatment
option for COVID-19. These guidelines are exclusively based
on the consensus of experts, and the data to support the rec-
ommendations are not detailed. Following we provide a more
detailed description of these guidelines.
1. National Health Commission (NHC), National Admin-
istration of Traditional Chinese Medicine, sixth edition32
We consulted two documents related to this guideline: the
full guideline,32 which contained the sixth version of the diag-
nosis and treatment plan for COVID-19, and a report with the
seventh version of this chapter.31 The guideline claims that
‘‘COVID-19 can also be treated with Traditional Chinese
Medicine’’ and describes in detail (including formulas and
compounds) an exhaustive list of CHMoptions according to the
clinical situation of the patient, covering from patients with
‘‘fatigue with gastrointestinal upset’’ to ‘‘critical patients.’’ For
example, the guideline recommends administering Xue Bi Jing
injection 100mL/day, twice a day for the treatment of severe
and critical cases. For patients with ‘‘fatigue with gastrointes-
tinal upset,’’ Huoxiang Zhengqi (capsule/pill/oral liquid) is re-
commended. More examples of suggested CHM interventions
are Qingfei Paidu decoction (QPD), Gancao Ganjiang decoc-
tion, Shegan Mahuang decoction, or Qingfei Touxie Fuzheng
decoction (seemore details in Ren et al.46 and the guidelines).32
The authors state that ‘‘the guidelines were written based on
the study, analysis and summary of the treatment of previous
COVID-19 cases.’’ However, it seems that the recommenda-
tions are based on the experts’ experience, and no empirical data
are provided to support these recommendations. It is also unclear
how the guideline team managed their potential conflicts of in-
terest, it seems that there was not a rigorous search of the liter-
ature, and there was no assessment of the quality of evidence.
2. Jin et al.30
According to this article, these guidelines were developed
according to the GRADE approach and the WHO guideline
development manuals. However, the recommendations for
the treatment of COVID-19 with CHMs are based on the
guideline already described.32 Thus, the same conclusions
on the limitations apply to these recommendations.
3. The First Affiliated Hospital, Zhejiang University
School of Medicine33
This guideline synthesizes the clinical experience of The
First Affiliated Hospital, Zhejiang University School of
Medicine (FAHZU), in the treatment of COVID-19. The
guide also has a section dedicated to CHMs. However, it has
the same weaknesses of the previous two guidelines.
4. Association of Korean Medicine, Korean Association
of Traditional Pulmonary Medicine38
These guidelines recommend the use of CHMs for the
treatment of COVID-19 and they are also based on the con-
sensus of experts exclusively. The description of the methods
of the guidelines is incomplete, so it could not be known
whether there was a rigorous search strategy, the evidence that
was considered, or whether there was any attempt to assess the
certainty of the evidence.
Objective 2: To summarize the evidence on CHMs in pa-
tients with COVID-19
Systematic reviews (n= 1, indirect evidence). No sys-
tematic review of the effects of CHMs on the treatment of
patients with COVID-19 was found. One Cochrane review
published in 2012 was identified that evaluated the effects of
Chinese herbs combined with conventional medicine for
SARS.8 The review included 12 RCTs and 1 quasi-RCT.
The review concluded that Chinese herbs plus conventional
medicine did not reduce mortality in patients with SARS, as
compared with conventional medicine alone. Besides, the
review suggested that the addition of the Chinese herbs may
have a beneficial impact on the following outcomes:
symptoms, absorption of pulmonary infiltration, the average
daily dose of corticosteroids, the dosage of corticosteroids,
days of corticosteroid treatment, quality of life, and length
of stay in hospital.47–56 It was considered that the potential
benefits identified in this Cochrane review cannot be directly
transferred to patients with COVID-19 because the results
obtained from patients with SARS may not apply to patients
with COVID-19. Besides, as highlighted in the Cochrane
review, the quality of the evidence was low.
RCTs (n = 0). There is no current evidence from RCTs to
recommend any specific anti-nCoV treatment for patients
with suspected or confirmed COVID-19.40 Thus, the same
conclusion applies to CHMs.
Observational studies (n = 5). Hereunder, five observa-
tional studies describing the effects of different preparations
of CHMs in patients with COVID-19 are presented. All
these studies are descriptive (without a comparator) with
small samples. Three studies are case reports (less than five
patients in total),46,57,58 and one study is a series of 214
cases.9 The remaining study did not report the sample size.59
All these studies share the common pitfalls inherent to
uncontrolled designs, which do not allow determining the
effects of an intervention; they can only suggest that there
may be an effect. In addition to that, there was a poor report
of the CHM compounds and the conventional treatment
received.
1. Ren et al.46,60
According to this one-case report, described in two arti-
cles,46,60 an early intervention with CHMs based on a plant-
based mixture called QPD prevented the severe and critical
disease in one patient with suspected COVID-19. This case
report raises serious concerns mainly because it describes
the success of just one patient and because the patient was
not confirmed as suffering from COVID-19.61,62
2. Yang et al.9
According to this report, the State Administration of
Traditional Chinese Medicine has recently recommended
combining CHMs and conventional medicine for the treat-
ment of COVID-19 pneumonia. As an example, QPD has
been devised to be used in viral infections. According to
Yang et al., in the 214 cases who received this treatment, the
symptoms disappeared quickly, and there was a rapid dis-
ease recovery.
3. Wang et al.58
This report described the care provided to four patients with
mild-to-severe COVID-19. The patients received antiviral
treatment (including lopinavir/ritonavir and arbidol), Shufeng
Jiedu capsule, that is, a CHM herbal formula, and other nec-
essary supportive care. The authors stated that Shufeng Jiedu
capsule may alleviate acute lung injury in patients with
COVID-19 and warrants further investigations.58


























































4. Kaijin Xu et al.
This report describes the experience of treating patients with
COVID-19 at the main hospital in Zhejiang (the number of
patients treated is not reported). The authors state that they
‘‘[.] also integrated Chinesemedicine in treatment to promote
disease rehabilitation through classification methods of tradi-
tional Chinese medicine.’’ However, only the abstract could be
accessed, which describes the intervention vaguely and does
not provide any outcome measure to prove treatment effects.
5. Ni et al.57
This report describes the first family case of COVID-19
confirmed in Wuhan. The three family members (parents and
daughter) responded poorly to routine conventional treat-
ments, so they also received Shuang Huang Lian (SHL) oral
liquid, a Chinese Traditional patent Medicine. SHL contains
extracts of three Chinese herbs, namely, honeysuckle, for-
sythia, and Scutellaria baicalensis, and is used to treat sore
throat, cold, and cough with fever. The report highlights that
‘‘the three cases [.] achieved rapid recovery’’ and suggests
that SHL treatment might be effective. Thus, the authors have
started a clinical trial (ChiCTR2000029605) to assess the ef-
fects of SHL for the treatment of COVID-19. This multicenter
nonblinded RCT seems to have started in February 2020.
Other studies (n = 3). To identify treatment options as soon
as possible is critical to alleviating the impact of the COVID-19
outbreak. The WHO has published a list of candidate thera-
peutics,63 which does not include any CHM intervention.
However, CHMs for the treatment of COVID-19 are still con-
sidered in China as an area that requires further clinical re-
search.64 Zhang et al.11 proposed a system to screen CHM
compounds that may be candidates against COVID-19. This
approach has identified 13 natural compounds that exist in
Chinese herbs with potential anti-SARS-CoV-2 activity. In to-
tal, 125Chinese herbs contain 2 ormore of these 13 compounds.
Objective 3: To provide an overview of the ongoing RCT of
CHMs in patients with COVID-19
This search in the Cochrane COVID-19 Study Register
threw a total of 521 ongoing trials on interventions to treat
COVID-19 with a randomized or unclear assignment. After
screening all these records, 52 ongoing trials were identified
on the effects of CHMs for the treatment of COVID-19
(Table 1). These CHM trials represent 5.6% of the 921 trials
of the Cochrane COVID-19 Study Register (consulted on
April 23, 2020). In total, 46 out of the 52 trials (88%) were
registered on the Chinese Clinical Trial Registry (ChiCTR),
whereas only 6 (12%) in ClinicalTrials.gov. All the trials but
one (NCT04322344; Italy) will be conducted in China.
Forty (77%) of the ongoing studies on CHMs have been
planned to assign the participants to the study arms after a
random sequence. The remaining 12 trials (23%) did not
report whether they were randomized or not, so we assumed
they were not. The planned sample sizes of the trials ranged
from 20 to 550 participants (median 120 participants). Only
five trials (10%) planned to obtain a sample of at least 400
participants. The trials will evaluate the effects of different
herbal products administered orally (n = 40, 77%) or by in-
jection (n= 12, 23%). In 11 (27.5%) of the 40 trials evalu-
ating oral CHMs, the administration form (capsule,
granules, tablets, liquid, etc.) was not reported. Table 1 lists
all the CHM products that were evaluated. Besides, other
nine studies assessing the effects of TCM in patients with
COVID-19 were found, but could not conclude whether they
focused on CHMs due to poor reporting of the interventions.
Discussion
Summary of main results
A total of 25 guidelines were identified on the treatment of
patients with COVID-19. Only four guidelines, all developed
in China and South Korea, included recommendations on the
use of CHMs. These recommendations on herbal medicines
were based on the consensus of experts exclusively.
This review did not find reliable evidence on the effects of
any specific CHM intervention for the treatment of patients with
COVID-19. No finished RCT was identified. In contrast, indi-
rect evidence provided in a Cochrane review published in 2012
was found on the effects of Chinese herbs combined with
conventional medicine in patients with SARS. This Cochrane
review concluded that Chinese herbs did not reduce mortality,
but that they may have a beneficial effect in several clinical
outcomes, such as symptoms, or the absorption of pulmonary
infiltration. However, the review authors rated the quality of the
evidence as low. Thus, we judged that the indirect evidence
obtained from this review does not suffice to consider that CHM
interventions have an impact on COVID-19. Five observational
studies were also found pointing to a benefit associated with the
use of CHMs. All these studies were uncontrolled designs, with
small sample sizes and poor reporting, and they do not allow
determining the effects of a health care intervention.
This review highlights the need of RCTs to determine the
benefits and harms of CHMs for the treatment of COVID-
19. A total of 52 ongoing trials evaluating the effects of
different Chinese herbal products for the treatment of
COVID-19 were found. This is an important step to get solid
findings. All the studies but one will take place in China and
40 out of the 52 seem randomized designs.
Potential biases in the review process
The main limitation of this review is its narrative ap-
proach. However, the authors tried to state a clear set of
objectives with predefined eligibility criteria for the studies.
In this line, a review question was formulated according to
the PICO-D format, that is, defining the participants, inter-
ventions, comparators, outcomes, and the eligible study
designs. Also, it was attempted to reduce the risk of publi-
cation bias, as demonstrated hereunder.
It is acknowledged that this review did not search in several
relevant electronic databases, such as Embase or the Chinese
Biomedical Literature. However, MEDLINE (through
PubMed) and CENTRAL were consulted (the latter is the lar-
gest database of trials in the world). Also, the authors were able
to translate documents fromChinese andKorean toEnglish, and
contacted Chinese experts asking for relevant trials in the field.
Another weakness of this review is that a direct search of
the ChiCTR for ongoing trials was not done. However,
ChiCTR is indexed in the WHO ICTRP platform, which, in
turn, can be accessed from the Cochrane COVID-19 Study
Register, the tool consulted in this review.
The Institute forComplementary and IntegrativeMedicine14
(Zurich University Hospital) hosts Cochrane Complementary


























































Table 1. Ongoing Trials on Chinese Herbal Medicines for the Treatment
of Coronavirus Disease 2019 (in Alphabetical Order)
Herbal product Presentation Study design Sample size Identification
Oral administration
Ba Bao Dan Capsules RCT 40 ChiCTR2000029769
Diammonium glycyrrhizinate Capsules RCT 60 ChiCTR2000029768
Capsules Non-RCT 100 ChiCTR2000030490
Escin Not reported Non-RCT 120 NCT04322344
Exocarpium citri grandis Not reported RCT 128 ChiCTR2000030804
Honeysuckle decoction Oral liquid Oral liquid RCT 110 ChiCTR2000029822
Oral liquid RCT 300 ChiCTR2000029954
Huai Er Granules RCT 550 NCT04291053
Huashi Baidu Granules RCT 204 ChiCTR2000030988
Huatan Zhike pediatric Granules RCT 100 ChiCTR2000030022
Lianhua Qingwen Capsule/granules RCT 240 ChiCTR2000029433
Capsule/granules RCT 240 ChiCTR2000029434
Liu Shen Wan (LSW) Not reported RCT 96 ChiCTR2000030469
Liu Shen Capsule RCT 40 ChiCTR2000029993
Qingfei Paidu Not reported RCT 180 ChiCTR2000029855
Not reported Non-RCT 50 ChiCTR2000030864
Qingwen Baidu Yin Granules RCT 20 ChiCTR2000030166
Qingyi No. 4 compound Granules RCT 200 ChiCTR2000029947
Jing Yin Granules RCT 300 ChiCTR2000030255
Jingye Baidu Granules RCT 120 ChiCTR2000029755
Kang Guan Nos. 1–3 Oral solution RCT 120 ChiCTR2000030215
KeSu Ting (group 1) or Ke Qing (group 2) Syrup RCT 72 ChiCTR2000029991
Capsule
Kang Bingdu Granules RCT 160 ChiCTR2000029781
Maxing Ganshi decoction Not reported RCT 100 ChiCTR2000030522
Shenling Baizhu Powder Non-RCT 120 ChiCTR2000029956
Shuang Huang Lian Oral solution RCT 400 ChiCTR2000029605
Tan Re Qing (TRQ) Capsules RCT 72 ChiCTR2000029813
Traditional Chinese Medicine formula nr.
1 or 2 or 3 or 4 or 5 or 6
Not reported RCT 400 ChiCTR2000030923
Traditional Chinese Medicine Formula
No. 1 and 2 (group 1) or
Not reported RCT 480 ChiCTR2000030003
Ganke Shuangqing (group 2) or Capsule
Shuang Huang Lian (group 3) Oral solution
Traditional Chinese Medicine decoction
(Huoxiang 9 g, Magnolia 9 g, Yinhua
9 g, Atractylodes 9 g, Cicada 6 g, Su Ye
6 g, Poria 15 g, Huai yam 15 g)
Not reported RCT 100 ChiCTR2000029517




Traditional Mongolian medicine Not reported Non-RCT 60 ChiCTR2000030751
Truncation and torsion formula Not reported RCT 300 ChiCTR2000029869
Not reported Non-RCT 300 ChiCTR2000030836
Yiqi Huashi Jiedu Fang Not reported RCT 100 ChiCTR2000030479
Yinhu Qingwen Granules RCT 116 NCT04310865
Granules RCT 300 NCT04278963
Injection
ReDuNing (RDN) Non-RCT 60 ChiCTR2000029589
Shenqi Fuzheng RCT 160 ChiCTR2000029780
Shenfu RCT 300 ChiCTR2000030043
Sodium Aescinate injection RCT 90 ChiCTR2000029742
Tan Re Qing (TRQ) Non-RCT 72 ChiCTR2000029432




Xuebi Jing RCT 60 ChiCTR2000030388
Non-RCT 400 ChiCTR2000029381
Zedoary turmeric oil RCT 60 ChiCTR2000030518



























































Medicine Switzerland,65 a satellite group of Cochrane Com-
plementary Medicine.66 Cochrane Complementary Medicine
is a field established in Cochrane ‘‘in 1996 to support and
promote systematic reviews of complementary, alternative,
and integrative therapies and to function as a link between
Cochrane, a worldwide organization that prepares systematic
reviews of all kinds of health care therapies, and practitioners,
researchers, and consumers with an interest in complementary
medicine.’’ On April 7, 2020, Cochrane launched its COVID-
19 Study Register16 to support rapid evidence synthesis by all
systematic review producers. This tool was used to identify
ongoing RCTs on CHMs for the treatment of COVID-19. This
register was helpful as it allowed searching the ongoing trials
on COVID-19 from one source.
It is also acknowledged that the search strategy in MED-
LINE focused on Chinese herbal products, the topic of this
review. This might have hampered the identification of rel-
evant guidelines or studies on herbal products used in other
Asian countries and not categorized as ‘‘Chinese.’’ However,
it is still considered that this search strategy allowed identi-
fying the most relevant evidence. First, because the search
strategy in MEDLINE also used MeSH terms related to
herbal products in general, and not only the Chinese products
(‘‘Oriental Traditional Medicine’’ and ‘‘Medicinal Plants’’).
Second, other sources than MEDLINE were searched, such as
databases collecting guidelines (e.g., Trip Medical Database)
or the bibliographies of relevant documents.
Agreements and disagreements
with other studies or reviews
This review did not find reliable evidence on the effects
of any specific CHM intervention for the treatment of pa-
tients with COVID-19. This conclusion is consistent with
previous analyses that concluded that, to date, there is no
intervention recommended to treat SARS-CoV-2.40
The lack of reliable evidence of the benefits of CHMs in
patients with COVID-19 does not support the expectations that
CHMswould be a valuable treatment againstCOVID-19.64,67–70
For example, there is no evidence on the effects of CHMs on
critical outcomes in the context of the current pandemic, such as
the length of hospital stay. A reduced length of stay of patients
with COVID-19 is an essential outcome to support decision
making in overloaded health care facilities worldwide.
However, the use of CHMs to contain SARS-CoV-2 has
been promoted in China,69 and the Chinese and South Korean
guidelines have endorsed the use of CHMs as a treatment
option for COVID-19.30–32,71 Besides, CHMs have been
widely used in China to treat patients with COVID-19.67 For
example, Yin Qiao powder, Huopo Xialing decoction,Maxing
Shigan decoction, Liang Ge powder, Qingwen Baidu decoc-
tion, and Da Yuan decoction have been widely prescribed for
the treatment of COVID-19.72 Also, *85% of the total
confirmed COVID-19 cases may have received TCM inter-
ventions.69 In fact, Qingfei Paidu Tang is recommended in
the Chinese and the Korean guidelines.71
Although CHMs have been proposed in China as a treat-
ment option in patients with COVID-19, its efficacy and safety
still need to be confirmed by well-designed clinical studies.
The website of the National Center for Complementary and
Integrative Health in the United States explicitly states that
‘‘There is no scientific evidence that any of these alternative
remedies can prevent or cure the illness caused by this vi-
rus.’’73 Besides, as this site highlights, some alternative treat-
ments may not be safe to consume.73,74 Gray and Belessis
brought up the point that the use of CHMs to treat SARS-CoV-
2 may cause harm75 due to its potential for iatrogenic lung
injury (interstitial pneumonitis).75,76 Also, the interactions of
the herbs with conventional treatment should be carefully as-
sessed.69,77 Therefore, the benefit–risk balance for CHMs
needs to be carefully evaluated and acknowledged.
All the Chinese guidelines evaluated in this review rec-
ommend the use of CHMs in combination with conventional
medicine for the treatment of COVID-19. This finding may
lead us to think that the inclusion of TCM-related infor-
mation in Chinese clinical guidelines is the norm. However,
of a total of 604 Chinese clinical practice guidelines on
Western medicine, only a small number (74/604; 12%) re-
commended the use of TCM therapy.5
All the Chinese national guidelines identified in this over-
view recommend herbal medicines for the management of
COVID-19, and health care professionals in China have used
them frequently in patients with COVID-19. Interestingly, as
already stated, only 12% of the Chinese biomedical clinical
guidelines for other diseases recommended CHMs.5 This gap
might be explained by the fact that there has not been an ef-
fective treatment against COVID-19 so far. Nevertheless, ex-
treme situations such as COVID-19 seem to change the
processes to generate, synthesize, and implement the evidence,
and how all the relevant stakeholders involved (policy makers,
guideline developers, and health care professionals) contribute.
A deeper understanding of how the evidence ecosystem adapts
to a pandemic might be an interesting topic of future research.
This review highlights that so far no recommendation of
CHMs in the Chinese guidelines was developed according
to transparent, explicit, and rigorous methods. This finding
is compatible with the results of another study, which found
that only 9% (7/74) of the Chinese clinical guidelines pro-
viding recommendations on TCMs had followed a system to
grade the evidence and develop the recommendations.5
This review found a high number of trials (n = 52) that are
currently running to determine the effectiveness of CHMs
for the treatment of COVID-19. However, 12 of these trials
will be nonrandomized, and only 5 trials will have a sample
size of at least 400 participants. Small samples imply that
most of the ongoing trials will not be powered enough to
detect differences in the primary outcome of the study.
Besides, 27.5% of the trials evaluating oral CHMs did not
report the form of administration (capsule, granules, tablets,
liquid, etc.). Also, nine additional ongoing trials were found
with a poor reporting that prevented knowing whether they
were planning to evaluate CHMs. These findings are broadly
compatible with the results of previous studies, which
highlighted that the COVID-19 trials on TCM registered so
far were poorly reported and small sized, thus they might
not provide reliable information for decision making.69,78,*,
{
*Zhu RF, et al. Preprint of a not peer-reviewed article.
MedRxiv. 2020. Online document at: www.medrxiv.org/content/
10.1101/2020.03.01.20029611v2, accessed March 19, 2020.
{Qiu R, et al. Preprint of a not peer-reviewed article. MedRxiv.
2020. Online document at: www.medrxiv.org/content/10.1101/
2020.03.04.20031401v1, accessed March 19, 2020.




























































To the authors’ knowledge, only the Chinese and the
South Korean guidelines recommend CHMs as a treatment
option for patients with COVID-19. These guidelines ex-
clusively base their recommendations on the consensus of
experts. Clinical guidelines or health authorities from other
countries do not provide advice on CHMs.
There is currently no reliable evidence on the effects of any
specific CHM intervention for the treatment of patients with
COVID-19. No completed RCTs on CHMs were found for
the treatment of patients with COVID-19. According to the
evidence evaluated in this review, a Cochrane review of
CHMs for SARS and five uncontrolled observational studies,
the effects of CHMs for COVID-19 are unknown.
Implications for research
Well-designed and adequately powered RCTs to deter-
mine the effects (benefits and harms) of CHMs in patients
with COVID-19 are needed. A high number of RCTs of
different herbal products are being conducted in China.
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Appendix A1. Sources Consulted and Search Strategies
Electronic Databases (All accessed April 23, 2020)
MEDLINE (through PubMed)
Query Records
1 Search ‘‘Drugs, Chinese
Herbal’’[Mesh]
42,843
2 Search ‘‘Medicine, Chinese
Traditional’’[Mesh]
18,663
3 Search ‘‘Medicine, East Asian
Traditional’’[Mesh]
21,720
4 Search Plants, Medicinal/ 72,774
5 Search chinese herb* (Ti, ab or
keywords)
49,329






Plants, Medicinal/) OR chinese
herb*
129,224
7 Search coronavirus covid-19 (Ti,
ab or keywords)
3393
8 Search ‘‘Coronavirus disease
2019’’ (Ti, ab or keywords)
985
9 Search ‘‘2019 novel coronavirus’’
(Ti, ab or keywords)
440
10 Search ‘‘2019-nCoV’’ (Ti, ab or
keywords)
533
11 Search (((coronavirus covid-19)
OR ‘‘Coronavirus disease
2019’’) OR ‘‘2019 novel
coronavirus’’) OR ‘‘2019-
nCoV’’ (Ti, ab or keywords)
3556
12 Search #6 AND #11 35
The Cochrane Library, which contains
the following sources:
 The Cochrane Central Register of Controlled Trials
(CENTRAL) 2020, Issue 3 (which contains the Acute
Respiratory Infection Group’s Specialised Register)
 Cochrane Database of Systematic reviews
Query Records
1 Search coronavirus covid-19 (Ti, ab
or keywords)
2 Search ‘‘Coronavirus disease 2019’’
(Ti, ab or keywords)
3 Search novel near coronavirus (Ti, ab
or keywords)
4 Search nCoV (Ti, ab or keywords)
5 Search {OR #1–#4}
Results in Cochrane Database of
Systematic Reviews
3
Results in CENTRAL 56
2. Other Sources
a. Epistemonikos (‘‘Evidence for COVID’’)
b. Tripdatabase
c. MEDBOX Rapid Response Toolbox




h. Websites of relevant organizations
1. Centers for Disease Control and Prevention (CDC)
2. European Centre for Disease Prevention and Control
(ECDC)
3. The National Institute for Health and Care Ex-
cellence (NICE)
4. National University of Singapore Saw Swee Hock
School of Public Health
5. U.S. National Center for Complementary and Al-
ternative Medicine
6. JAMA resources on COVID-19
7. CEBM Oxford COVID-19 Evidence Service
i. Contact of experts in the field
Experts in China were contacted asking for relevant
studies or guidelines.
j. Bibliographies of systematic and narrative reviews
3. Trial Registries (To Identify Ongoing Studies)
The Cochrane COVID-19 Study Register was consulted.
Query Records
1 Study type: interventional 33
2 Study aim: treatment management 3
3 Intervention assignment: randomized
or unclear
27
4 Search {OR #1–#4} 521
The 521 records to endnote were imported, where the
selection process was performed by reading the titles of all
records. Besides, searches of specific terms in endnote were
implemented to check that no relevant study was missing.
The following terms were used: Traditional OR Chinese OR
Herb or TCM OR decoction OR Qingyi OR Western med-
icine OR Feidian OR glycyrrhiza OR Lian-Hua OR Huo-
Shen OR Xiyanping OR Kang-Bing-Du OR Zedoary OR
turmeric OR oil OR Xue-Bi-Jing OR Shen-Fu OR Capsule
OR granule.
Appendix A2. Documents Consulted
Guidelines (n= 25)
International (n= 4)
1. World Health Organization (WHO).A1
2. World Health Organization (WHO).A2
3. European Centre for Disease Prevention and Control
(ECDC).A3
(Appendix continues/)


























































4. Surviving Sepsis Campaign: guidelines on the man-
agement of critically ill adults with coronavirus dis-
ease 2019 (COVID-19)A4
America (n= 8)
Canada (n = 3)
1. Government of Canada.A5
2. Government of Canada.A6
3. British Columbia Centre for Disease Control
(BCCDC).A7
United States (n= 5)




5. American Colleague of Obstetrician and Gynecolo-
gists, Society for Maternal-Fetal Medicine.A12
Asia (n =6)
China (n = 3)
1. National Health Commission (NHC), National Ad-
ministration of Traditional Chinese Medicine, Sixth
Edition.A13
2. Jin et al.A14
3. The First Affiliated Hospital, Zhejiang University
School of Medicine.A15
Malaysia (n = 1)
1. Ministry of Health of Malaysia.A16
South Korea (n= 2)
1. South Korean physicians treatment guidelines.A17
2. Traditional medicine guidelines on the prevention and
treatment of COVID-19, first edition, February 25,
2020 (the Association of Korean Medicine and the
Korean Association of Traditional Pulmonary Medi-
cine)A18
Europe (n= 5)
United Kingdom (n= 4)
1. Public Health England.A19
2. Health Protection Scotland (HPS).A20
3. National Institute for Health and Care Excellence
(NICE).A21
4. National Institute for Health and Care Excellence
(NICE).A22
Germany (n = 1)
1. Robert Koch Institute.A23
Oceania (n =2)
Australia (n =2)
1. The Australian and New Zealand Intensive Care So-
ciety (ANZICS).A24
2. Australia National COVID-19 Clinical Evidence
Taskforce.A25
Systematic Reviews (n =1)
A Cochrane reviewA26 was found published in 2012 as-
sessing the effectiveness and safety of Chinese herbs com-
bined with conventional medicines versus conventional
medicines alone for patients with ‘‘severe acute respiratory
syndrome’’ (SARS). SARS was recognized in 2003 and
caused by another coronavirus, known as SARS CoV. An-
other systematic review has proposed a system to identify
herbal components of TCM that may have an effect on
COVID-19.A27
Evidence Summaries (n= 3)
1. BMJ Best practice: Coronavirus disease 2019
(COVID-19)A28
2. UpToDate. Coronavirus disease 2019 (COVID-19)
(version March 16, 2020)A29
3. DynaMed. COVID-19 (Novel Coronavirus)A30
Randomized Controlled Trials (n =0)
No finished randomized controlled trials was found to
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